What is right and wrong concerning immune therapy and Intralipid treatment in Reproduction?

An increasing number of clinics offer immune treatment prior to IVF.

The key to understand when to use heparin, aspirin, immunoglobulin and Intralipid in women suffering from recurrent implantation failure or abortus habitualis is the present of antiphospholipid antibodies (APA ) and natural killer cell NKC activity.

The knowledge about the immune system and implantation in early pregnancy has led to the identification of a few key processes: This is the coagulation system, the function of the natural killer cells and the presents of antiphospholipid antibodies.

There are 2 groups of repeated failed in IVF treatments:

The women who never become pregnant - nor gets a positive pregnancy test, they are called recurrent implantation failure.
abortus habitualis patients, this is women who become pregnant but repeatedly loses fetus within the first approx. 8-10 weeks of pregnancy.

A recent publication American Journal of Reproductive Immunology demonstrates in a review article the following:

APA is equally frequently elevated in women receiving IVF treatment diagnosed as unexplained infertility, "recurrent implantation failure or abortus habitualis.

Heparin and aspirin has a positive effect on pregnancy rate in women with elevated APA suffering from abortus habitualis, but not in women suffering from recurrent implantation failure.

Immunoglobulin on the other hand has a positive effect on pregnancy rate in IVF treatment both in women with recurrent implantation failure and abortus habitualis , but only when the women had elevated APA or NKC activities.

Intralipid is just as effective at this as immunoglobulin treatment, and especially in women in IVF treatment with many treatments without success and increased NKC activity.

The question is therefore definitively:

Helps immunotherapy in IVF treatment on the number of live births, and the answer is yes, but especially effective when you have found the cause and correct it.

Immunotherapy and Intralipid are equally effective in normalizing NKC activity and improves the chances of giving birth to a child when they have been diagnosed with high NKC activity.

Reference:

https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0897.2012.01111.x/pdf